Q4 EPS Estimates for OTCMKTS:BSEM Raised by Zacks Small Cap

BioStem Technologies, Inc. (OTCMKTS:BSEM) – Stock analysts at Zacks Small Cap lifted their Q4 2024 earnings per share (EPS) estimates for BioStem Technologies in a report issued on Friday, November 15th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of $0.37 per share for the quarter, up from their prior estimate of $0.32. The consensus estimate for BioStem Technologies’ current full-year earnings is $1.13 per share. Zacks Small Cap also issued estimates for BioStem Technologies’ Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.61 EPS and FY2026 earnings at $2.39 EPS.

BioStem Technologies Stock Performance

Shares of BSEM opened at 12.70 on Monday. BioStem Technologies has a one year low of 2.34 and a one year high of 28.26. The stock’s fifty day moving average is 13.60 and its 200-day moving average is 10.77. The firm has a market capitalization of $211.07 million, a price-to-earnings ratio of 18.68 and a beta of -0.36.

BioStem Technologies (OTCMKTS:BSEM) last posted its earnings results on Tuesday, November 12th. The company reported 0.32 EPS for the quarter, beating the consensus estimate of 0.31 by 0.01. The business had revenue of 82.56 million during the quarter, compared to analyst estimates of 78.22 million.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.